Evidence map›Paper›PMID 37867702›Full record

ArticleACS omega2023

Neuroprotective Activity of Enantiomers of Salsolinol and

Magdalena Kurnik-Łucka, Gniewomir Latacz, Adam Bucki, Mario Rivera-Meza, Nadia Khan, Jahnobi Konwar, Kamil Skowron, Marcin Kołaczkowski, Krzysztof Gil

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Magdalena Kurnik-ŁuckaDepartment of Pathophysiology, Jagiellonian University Medical College, 31-008 Krakow, Poland.ORCID https://orcid.org/0000-0002-2853-769X
Gniewomir LataczDepartment of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, 31-008 Krakow, Poland.
Adam BuckiDepartment of Medicinal Chemistry, Jagiellonian University Medical College, 31-008 Krakow, Poland.ORCID https://orcid.org/0000-0003-0451-9814
Mario Rivera-MezaLaboratory of Experimental Pharmacology, Faculty of Chemical Sciences and Pharmaceutical Sciences, University of Chile, 8380494 Santiago, Chile.
Nadia KhanDepartment of Pathophysiology, Jagiellonian University Medical College, 31-008 Krakow, Poland.
Jahnobi KonwarDepartment of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, 31-008 Krakow, Poland.
Kamil SkowronDepartment of Pathophysiology, Jagiellonian University Medical College, 31-008 Krakow, Poland.
Marcin KołaczkowskiDepartment of Medicinal Chemistry, Jagiellonian University Medical College, 31-008 Krakow, Poland.ORCID https://orcid.org/0000-0001-8402-1121
Krzysztof GilDepartment of Pathophysiology, Jagiellonian University Medical College, 31-008 Krakow, Poland.
Jagiellonian University · PLUniversity of Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salsolinol (1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol) is a close structural analogue of dopamine with an asymmetric center at the C1 position, and its presence in vivo, both in humans and rodents, has already been proven. Yet, given the fact that salsolinol colocalizes with dopamine-rich regions and was first detected in the urine of Parkinson's disease patients, its direct role in the process of neurodegeneration has been proposed. Here, we report that

Identifiers

PMID37867702
PMCPMC10586258
OpenAlexW4387377291

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.